These data indicate that there is a new mTOR independent progranulin-related pathway in the proliferation of Kasumi-1 cells, and progranulin will be a target of new therapeutic strategy to hematopoietic cancers. The gene discussed is MTOR; the disease is hematopoietic and lymphoid cell neoplasm.